Hossein-Ardeschir Ghofrani
Overview
Explore the profile of Hossein-Ardeschir Ghofrani including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
113
Citations
5546
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
41.
Hodgson J, Swietlik E, Salmon R, Hadinnapola C, Nikolic I, Wharton J, et al.
Am J Respir Crit Care Med
. 2019 Oct;
201(5):575-585.
PMID: 31661308
Recently, rare heterozygous mutations in were identified in patients with pulmonary arterial hypertension (PAH). encodes the circulating BMP (bone morphogenetic protein) type 9, which is a ligand for the BMP2...
42.
McLaughlin V, Vachiery J, Oudiz R, Rosenkranz S, Galie N, Barbera J, et al.
J Heart Lung Transplant
. 2019 Oct;
38(12):1286-1295.
PMID: 31648845
Background: The purpose of this study was to compare patients with pulmonary arterial hypertension enrolled in the AMBITION trial with (excluded from the primary analysis set [ex-primary analysis set]) and...
43.
White R, Vonk-Noordegraaf A, Rosenkranz S, Oudiz R, McLaughlin V, Hoeper M, et al.
Respir Res
. 2019 Sep;
20(1):208.
PMID: 31511080
Background: Initial combination therapy with ambrisentan and tadalafil reduced the risk of clinical failure events for treatment-naïve participants with pulmonary arterial hypertension (PAH) as compared to monotherapy. Previous studies in...
44.
45.
Torbicki A, Bacchi M, Delcroix M, Farber H, Ghofrani H, Hennessy B, et al.
Circ Cardiovasc Qual Outcomes
. 2019 May;
12(5):e005095.
PMID: 31109190
Background Conducting randomized controlled trials to investigate survival in a rare disease like pulmonary arterial hypertension has considerable ethical and logistical constraints. In many studies, such as the Study with...
46.
Weiss A, Neubauer M, Yerabolu D, Kojonazarov B, Schlueter B, Neubert L, et al.
Nat Commun
. 2019 May;
10(1):2204.
PMID: 31101827
Pulmonary arterial hypertension (PAH) is a devastating disease with poor prognosis and limited therapeutic options. We screened for pathways that may be responsible for the abnormal phenotype of pulmonary arterial...
47.
Chin K, Rubin L, Channick R, Di Scala L, Gaine S, Galie N, et al.
Circulation
. 2019 Apr;
139(21):2440-2450.
PMID: 30982349
Background: NT-proBNP (N-terminal pro brain natriuretic peptide) levels are included in the multiparametric risk assessment approach for pulmonary arterial hypertension (PAH) outlined in PAH guidelines. However, data supporting the use...
48.
Risk assessment in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
Humbert M, Farber H, Ghofrani H, Benza R, Busse D, Meier C, et al.
Eur Respir J
. 2019 Mar;
53(6).
PMID: 30923187
Background: Current pulmonary hypertension treatment guidelines recommend use of a risk stratification model encompassing a range of parameters, allowing patients to be categorised as low, intermediate or high risk. Three...
49.
Beghetti M, Channick R, Chin K, Di Scala L, Gaine S, Ghofrani H, et al.
Eur J Heart Fail
. 2019 Jan;
21(3):352-359.
PMID: 30632656
Aims: Patients with pulmonary arterial hypertension associated with congenital heart disease (CHD-PAH) after defect correction have a poor prognosis compared with other CHD-PAH patients. Therefore, it is important that these...
50.
Kim N, Delcroix M, Jais X, Madani M, Matsubara H, Mayer E, et al.
Eur Respir J
. 2018 Dec;
53(1).
PMID: 30545969
Chronic thromboembolic pulmonary hypertension (CTEPH) is a complication of pulmonary embolism and a major cause of chronic PH leading to right heart failure and death. Lung ventilation/perfusion scintigraphy is the...